Please login to the form below

Not currently logged in
Email:
Password:

muscular dystrophy

This page shows the latest muscular dystrophy news and features for those working in and with pharma, biotech and healthcare.

Ex-Pharmacyclics CEO invests $25m in Summit

Ex-Pharmacyclics CEO invests $25m in Summit

It’s also a boost to the UK company after the disappointment of its recent failed programme in Duchenne muscular dystrophy (DMD), which prompted its re-focusing as an anti-infectives

Latest news

More from news
Approximately 19 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US ... 2015 and in the EU 2016) and Spinraza (for the

  • Deal Watch - May 2017 Deal Watch - May 2017

    397. BMS (US). Roche (CH). Licence. Anti-myostatin adnectin pre phase 2 for Duchenne Muscular Dystrophy .

  • Deal Watch March 2017 Deal Watch March 2017

    The other asset purchase agreement was made by PTC Therapeutics, who acquired Emflaza, a steroid approved for Duchenne Muscular Dystrophy, from Marathon Pharmaceuticals for $140m upfront ($75m in cash and $65m ... 230. Marathon. PTC Therapeutics. Product

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/  Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Deal Watch October 2016 Deal Watch October 2016

    767. Sarepta (US). Summit (UK). Licence collaboration. Europe Utrophin modulator pipeline, lead molecule phase II for muscular dystrophy.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    Will help the firm develop its flagship Duchenne muscular dystrophy product. ... We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid

  • Summit appoints Pfizer/Bayer veteran as CMO Summit appoints Pfizer/Bayer veteran as CMO

    David Roblin to lead development of therapies for Duchenne muscular dystrophy and C.difficile. ... As our Duchenne muscular dystrophy and C difficile infection drug programmes go through patient clinical trials, David will make a major contribution to

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics